Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 11/20 | 0.66 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.62 |
| ▸ | NPY2R | P49146 | 3/20 | 0.60 |
| ▸ | GHSR | Q92847 | 2/20 | 0.60 |
| ▸ | NPY4R | P50391 | 3/20 | 0.60 |
| ▸ | NPY1R | P25929 | 2/20 | 0.60 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.60 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29461984 | 0.95 | NPBWR1 (0.62) | NPBWR1IL23RNPY2RGHSRNPY4R | |
| SCHEMBL29883780 | 0.95 | NPBWR1 (0.62) | NPBWR1IL23RNPY2RGHSRNPY4R | |
| SCHEMBL30254794 | 0.93 | IL23R (0.61) | NPBWR1IL23R | |
| SCHEMBL30512524 | 0.92 | IL23R (0.67) | NPBWR1IL23RNPY2RGHSR | |
| SCHEMBL31696777 | 0.91 | IL23R (0.66) | NPBWR1IL23R | |
| SCHEMBL31141444 | 0.90 | NPBWR1 (0.70) | NPBWR1IL23RNPY2RGHSRKISS1R | |
| SCHEMBL31680259 | 0.90 | NPBWR1 (0.60) | NPBWR1IL23RGHSR | |
| SCHEMBL31141456 | 0.88 | KISS1R (0.70) | NPBWR1KISS1R | |
| SCHEMBL30092956 | 0.88 | NPBWR1 (0.65) | NPBWR1NPY2RNPY4RNPY1RNPY5R | |
| SCHEMBL30097937 | 0.87 | IL23R (0.63) | IL23RNPY2RGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4711005-A2 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | Stealth BioTherapeutics Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250319152-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250263433-A1 | METHODS FOR REDUCING CD36 EXPRESSION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250255929-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12102659-B2 | Methods for the prevention or treatment of heart failure | CORNELL UNIVERSITY (US) | 2024-10-01 | — | — | US | disclosed |
| EP-4397314-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230285499-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE | CORNELL UNIVERSITY (US) | 2023-09-14 | — | — | US | disclosed |
| EP-4233887-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230149501-A1 | METHODS FOR REDUCING OXIDATIVE DAMAGE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4085920-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| US-20220296672-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT NEUROPATHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11376304-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11366104-B2 | Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-06-21 | — | — | US | disclosed |
| EP-4005582-A1 | TREATMENT OF LEFT VENTRICULAR REMODELING | Stealth BioTherapeutics Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-4000690-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | Stealth BioTherapeutics Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285499-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE | TNNI3, FABP3, TNNC1 | NPBWR1 463/4885IL23R 4061/4885NPY2R 696/4885 |
| US-11944662-B2 | Methods and compositions for preventing or treating ophthalmic conditions | CRYAA, CRYAB, IAPP | NPBWR1 712/4885IL23R 3422/4885NPY2R 198/4885 |
| US-20250255929-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | TNNI3, TNNT2, FABP3 | NPBWR1 773/4885IL23R 2859/4885NPY2R 2489/4885 |
| US-20220296672-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT NEUROPATHY | NGF, GAP43, PRPH | NPBWR1 202/4885IL23R 3024/4885NPY2R 395/4885 |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | NPBWR1 1695/4885IL23R 4208/4885NPY2R 2584/4885 |
| US-12102659-B2 | Methods for the prevention or treatment of heart failure | TNNI3, FABP3, TNNC1 | NPBWR1 463/4885IL23R 4061/4885NPY2R 696/4885 |
| US-11998585-B2 | Methods and compositions for increasing the dose of a chemotherapeutic agent | OPRL1, TSG101, NGF | NPBWR1 207/4885IL23R 2694/4885NPY2R 914/4885 |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | NPBWR1 1695/4885IL23R 4208/4885NPY2R 2584/4885 |
| US-20250319152-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | ARG2, TNNT2, MYLK2 | NPBWR1 515/4885IL23R 3807/4885NPY2R 313/4885 |
| US-11376304-B2 | Methods and compositions for the prevention and treatment of disease | COL2A1, ALPI, COL14A1 | NPBWR1 794/4885IL23R 1209/4885NPY2R 820/4885 |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TNNI3, TNNT2, MB | NPBWR1 4341/4885IL23R 4785/4885NPY2R 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.